These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36403110)

  • 1. Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy.
    Chitimus DM; Berling E; Garderet L; Venturelli N; Malfatti E; Authier FJ; Nicolas G; Laforêt P; Lefeuvre C
    Eur J Neurol; 2023 Mar; 30(3):745-748. PubMed ID: 36403110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapidly progressive myopathy: unveiling light chain amyloidosis as an initial manifestation of multiple myeloma: a case report and literature review.
    Kaminskiene P; Stojkovic T; Roos-Weil D; Reimbold P; Chanut A; Lacene E; Evangelista T
    Neuromuscul Disord; 2024 Aug; 41():51-55. PubMed ID: 38925009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teaching neuroimages: dyspnea as a presenting manifestation of amyloid myopathy.
    Ghosh PS; Thaera GM; Tracy JA
    Neurology; 2013 Dec; 81(24):e184. PubMed ID: 24323446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
    Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
    Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Blair HA
    Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of amyloid myopathy diagnosed during the treatment of myopathy associated with anti-signal recognition particle antibodies].
    Kawakami N; Katsuyama Y; Hagiwara Y; Yoshida H; Kim K; Harada K
    Rinsho Shinkeigaku; 2017 Apr; 57(4):168-173. PubMed ID: 28367947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal muscle involvement in systemic amyloidosis is often overlooked.
    Xu J; Zhou X; Wang Y; Liu W; Shan Y; Zhang D; Lv H; Zhao D; Dai T; Zhao Y; Li W; Liu F; Yan C
    Neuropathol Appl Neurobiol; 2024 Aug; 50(4):e12996. PubMed ID: 38982616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal gammopathy of renal significance (MGRS)-related AL amyloidosis complicated by amyloid myopathy: a case report.
    Ono E; Ishii A; Higashi Y; Koita N; Ayaki T; Tanigaki K; Takayanagi S; Kondo N; Sakai K; Endo S; Yokoi H; Matsubara T; Minamiguchi S; Nishino I; Takahashi R; Yanagita M
    BMC Nephrol; 2021 Feb; 22(1):74. PubMed ID: 33639890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
    Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
    Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.
    Rybinski B; Kocoglu M
    Am J Case Rep; 2021 Aug; 22():e933241. PubMed ID: 34421115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscle involvement with pseudohypertrophy in systemic light chain amyloidosis: Case report.
    Draghici M; Jercan A; Badelita SN; Irimia RM; Bastian AE; Dobrea C; Popescu M; Coriu D
    Medicine (Baltimore); 2021 Dec; 100(51):e28267. PubMed ID: 34941106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary Lymphadenopathy as an Initial Presentation of Systemic Amyloidosis: A Case Report and Literature Review.
    Kumar S; Grell GR; Joseph G; Wang JC
    J Investig Med High Impact Case Rep; 2022; 10():23247096221133191. PubMed ID: 36300416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
    Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
    Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
    Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
    N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
    Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
    Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
    Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
    J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myopathy in a patient with systemic AA amyloidosis possibly induced by psoriasis vulgaris: An autopsy case.
    Tanabe H; Maki Y; Urabe S; Higuchi I; Obayashi K; Hokezu Y
    Muscle Nerve; 2015 Dec; 52(6):1113-7. PubMed ID: 26179325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response matters in light chain amyloidosis, whatever it takes.
    Palladini G; Milani P
    Br J Haematol; 2024 Jul; 205(1):25-27. PubMed ID: 38842142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myopathy and mixed hyperlipoproteinemia as the first symptom of systemic AL-amyloidosis].
    Tosovský M; Soukup T; Bradna P; Maisnar V; Tycová V; Toms J; Prixová M
    Vnitr Lek; 2008 Oct; 54(10):1014-9. PubMed ID: 19009771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.